TABLE 6.
Univariate analysis of the correlation between laboratory parameters and adverse clinical outcome of cancer patients with COVID-19.
| Laboratory parameters | Alive (N = 94) | Death (N = 18) | p value |
|---|---|---|---|
| Erythrocyte count, ×1012/L | 3.69 ± 0.77 | 3.20 ± 0.99 | 0.02 a |
| Hemoglobin count, g/L | 113.63 ± 23.66 | 99.67 ± 31.06 | 0.033 a |
| Platelet count, ×109/L | 210.19 ± 102.75 | 177.72 ± 130.28 | 0.245 a |
| White blood cell count, ×109/L | 5.53 (4.30–7.85) | 8.94 (5.94–12.26) | 0.003 b |
| Lymphocyte count, ×109/L | 1.03 (0.79–1.57) | 0.86 (0.51–1.39) | 0.134 b |
| Neutrophil count, ×109/L | 3.69 (2.71–5.63) | 7.40 (3.66–10.95) | 0.003 b |
| Monocyte count, ×109/L | 0.42 (0.31–0.62) | 0.41 (0.20–0.65) | 0.542 b |
| Aspartate aminotransferase, U/L | 29.00 (20.00–45.00) | 35.50 (21.25–76.00) | 0.428 b |
| Alanine aminotransferase, U/L | 25.00 (18.00–37.00) | 23.50 (15.50–44.25) | 0.886 b |
| Alkaline phosphatase, U/L | 74.00 (61.00–104.00) | 103.00 (76.00–288.50) | 0.01 b |
| Creatinine, μmol/L | 65.00 (53.68–79.48) | 64.10 (54.18–106.68) | 0.556 b |
| Creatine kinase, U/L | 63.00 (40.50–88.50) | 64.50 (42.25–170.25) | 0.608 b |
| Lactate dehydrogenase, U/L | 222.50 (183.78–298.25) | 460.55 (223.75–639.25) | 0.001 b |
| CK-MB, ng/ml | 0.70 (0.40–1.10) | 1.35 (0.58–2.52) | 0.016 b |
| Troponin I, ng/L | 3.80 (1.90–10.25) | 14.10 (6.30–39.38) | 0.003 b |
| Fibrinogen, g/l | 4.28 ± 1.43 | 4.38 ± 1.62 | 0.788 a |
| D-dimer, mg/L | 0.90 (0.24–1.84) | 3.18 (0.01–6.57) | 0.324 b |
| Procalcitonin, μg/L | 0.09 (0.03–0.30) | 0.61 (0.36–2.52) | <0.001 b |
| CRP, mg/L | 24.10 (3.79–61.60) | 93.02 (77.45–182.25) | <0.001 b |
| IL-6, pg/ml | 10.10 (5.42–32.68) | 39.18 (24.70–89.36) | 0.001 b |
| TNF-α, pg/ml | 2.69 (2.10–3.58) | 2.26 (1.50–2.84) | 0.09 b |
| IL-4, pg/ml | 2.27 (1.63–3.34) | 2.10 (1.40–2.77) | 0.405 b |
| IL-2, pg/ml | 2.69 (2.39–3.53) | 2.59 (2.18–3.27) | 0.521 b |
| IL-10, pg/ml | 4.01 (2.70–5.38) | 5.34 (3.32–8.98) | 0.09 b |
| IFN-γ, pg/ml | 2.19 (1.63–3.29) | 1.78 (1.38–2.83) | 0.129 b |
| CD3 ratio, % | 69.90 ± 17.82 | 68.19 ± 14.08 | 0.764 a |
| CD4 ratio, % | 40.54 ± 14.13 | 37.15 ± 15.28 | 0.471 a |
| CD8 ratio, % | 26.27 ± 12.16 | 23.38 ± 8.64 | 0.453 a |
| CD4/CD8 ratio, % | 1.88 ± 1.03 | 1.75 ± 1.16 | 0.705 a |
CRP, C-Reactive Protein; CKMB, Creatine Kinase-MB; P < 0.05 was considered statistically significant.
a
Indicates that the SK normality test follows the normal distribution, and expressed as mean ± standard deviation.
b
Indicates that the SK normality test follows a non-normal distribution, and expressed as median (interquartile range).